Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy-Reference-Cited by-同舟云学术

Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy

Published:2023-01 Issue: Volume:78 Page:100177
ISSN:1807-5932
Container-title:Clinics
language:en
Short-container-title:Clinics

Author:

Gutic Bojana^ORCID,Bozanovic Tatjana^ORCID,Mandic Aljosa^ORCID,Dugalic Stefan^ORCID,Todorovic Jovana^ORCID,Stanisavljevic Dejana^ORCID,Dugalic Miroslava Gojnic^ORCID,Sengul Demet^ORCID,Detanac Dzenana A.^ORCID,Sengul Ilker^ORCID,Detanac Dzemail^ORCID,Soares José Maria^ORCID

Funder

FAPESP

Publisher

Elsevier BV

Subject

General Medicine

Reference39 articles.

1. The PD1:PD-L1/2 pathway from discovery to clinical implementation;Bardhan;Front Immunol,2016

2. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer;Yearley;Clin Cancer Res,2017

3. Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status;Shin;Ann Surg Oncol,2016

4. Blockade of programmed death-1 ligands on dendritic cells enhances T-cell activation and cytokine production;Brown;J Immunol,2003

5. Regulation of T cell activation and tolerance by PDL2;Zhang;Proc Natl Acad Sci USA.,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in Immunotherapy for Breast Cancer: Mechanisms, Efficacy, and Future Directions;Cureus;2024-08-31

2. Cogent integration of inflammatory biomarkers and perioperative complications of thyroid surgery in thyroidology;Revista da Associação Médica Brasileira;2024

3. The relationship of C-Reactive Protein to Albumin Ratio and interval debulking surgery outcome after neoadjuvant chemotherapy in ovarian cancer patients;Clinics;2024-01

4. Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma;Clinics;2024-01

5. Analysis of PD-1/PD-L1 variations in lung cancer and association with immunotherapeutic efficacy and prognosis: A nonrandomized controlled trial;Clinics;2024-01